The 9 analysts offering 12-month price forecasts for BioXcel Therapeutics Inc have a median target of 94.00, with a high estimate of 175.00 and a low estimate of 63.00. The median estimate represents a +169.03% increase from the last price of 34.94.
The current consensus among 9 polled investment analysts is to Buy stock in BioXcel Therapeutics Inc. This rating has held steady since April, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.95
Reporting Date May 18
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.